[go: up one dir, main page]

WO2010013975A3 - A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivative or its salt, and bisphosphonate - Google Patents

A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivative or its salt, and bisphosphonate Download PDF

Info

Publication number
WO2010013975A3
WO2010013975A3 PCT/KR2009/004295 KR2009004295W WO2010013975A3 WO 2010013975 A3 WO2010013975 A3 WO 2010013975A3 KR 2009004295 W KR2009004295 W KR 2009004295W WO 2010013975 A3 WO2010013975 A3 WO 2010013975A3
Authority
WO
WIPO (PCT)
Prior art keywords
bisphosphonate
salt
preventing
pharmaceutical composition
benzamidine derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2009/004295
Other languages
French (fr)
Other versions
WO2010013975A2 (en
Inventor
Jin Soo Lee
Yun Ha Hwang
Jei Man Ryu
Young Goo Jin
Ki Yoon Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dong Wha Pharm Co Ltd
Original Assignee
Dong Wha Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong Wha Pharm Co Ltd filed Critical Dong Wha Pharm Co Ltd
Priority to CN2009801335866A priority Critical patent/CN102149381A/en
Priority to CA2732864A priority patent/CA2732864A1/en
Priority to JP2011521047A priority patent/JP2011529876A/en
Priority to EP09803180A priority patent/EP2307016A4/en
Publication of WO2010013975A2 publication Critical patent/WO2010013975A2/en
Publication of WO2010013975A3 publication Critical patent/WO2010013975A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

The present invention provides a pharmaceutical composition for preventing or treating osteoporosis, comprising a benzamidine derivative or salt thereof and bisphosphonate for the purpose of using simultaneously, separately, or sequentially as active ingredients. As a prophylactic or therapeutic composition for osteoporosis, the combination treatment of the benzamidine derivative and the bisphosphonate compound exhibits excellent inhibitory effect on osteoclast differentiation than the total effect of each individual treatment, thereby being used for the prevention or treatment of osteoporosis.
PCT/KR2009/004295 2008-08-01 2009-07-31 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivative or its salt, and bisphosphonate Ceased WO2010013975A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN2009801335866A CN102149381A (en) 2008-08-01 2009-07-31 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivative or its salt, and bisphosphonate
CA2732864A CA2732864A1 (en) 2008-08-01 2009-07-31 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivative or its salt, and bisphosphonate
JP2011521047A JP2011529876A (en) 2008-08-01 2009-07-31 Pharmaceutical composition for preventing or treating osteoporosis, comprising a benzamidine derivative or a salt thereof and bisphosphonate
EP09803180A EP2307016A4 (en) 2008-08-01 2009-07-31 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING A BENZAMIDINE DERIVATIVE OR A SALT THEREOF, AND BISPHOSPHONATE

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20080075791 2008-08-01
KR10-2008-0075791 2008-08-01
KR1020090007774A KR20100014090A (en) 2008-08-01 2009-01-31 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivative or its salt, and bisphosphonate
KR10-2009-0007774 2009-01-31

Publications (2)

Publication Number Publication Date
WO2010013975A2 WO2010013975A2 (en) 2010-02-04
WO2010013975A3 true WO2010013975A3 (en) 2010-06-03

Family

ID=42087985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/004295 Ceased WO2010013975A2 (en) 2008-08-01 2009-07-31 A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivative or its salt, and bisphosphonate

Country Status (6)

Country Link
EP (1) EP2307016A4 (en)
JP (1) JP2011529876A (en)
KR (2) KR20100014090A (en)
CN (1) CN102149381A (en)
CA (1) CA2732864A1 (en)
WO (1) WO2010013975A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
CA2732863A1 (en) * 2008-08-01 2010-02-04 Dong Wha Pharmaceutical Co., Ltd. A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivatives or their salts, and alendronic acid or its salt
EP3039022A4 (en) * 2013-08-29 2017-08-16 Baylor College Of Medicine Compositions and methods for the treatment of metabolic and body weight related disorders
CN107004844B (en) 2014-09-29 2020-07-21 A123系统有限责任公司 Prelithiated silicon anode with PVDF binder
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
EP4114529A1 (en) 2020-03-03 2023-01-11 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2023028238A1 (en) 2021-08-25 2023-03-02 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
US12234231B2 (en) 2021-08-25 2025-02-25 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451700A (en) * 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
US6150390A (en) * 1997-02-04 2000-11-21 Dong Wha Pharm. Ind. Co., Ltd. 3-amino-1,2-benzoisoxazole derivatives, process for preparation, and use thereof
WO2003007947A1 (en) * 2001-07-19 2003-01-30 Dong Wha Pharm. Ind. Co., Ltd. Use of 4-[(4-thiazolyl)phenoxl] alkoxy-benzamidine derivatives for treatment of osteoporosis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
AR024462A1 (en) * 1999-07-01 2002-10-02 Merck & Co Inc PHARMACEUTICAL TABLETS
KR100317935B1 (en) * 1999-10-20 2001-12-22 유승필 Pharmaceutical compositions and preparations for treatment of metabolic bone disease
JP2003292453A (en) * 2002-04-02 2003-10-15 Asahi Kasei Corp Pharmaceutical combination for bone disease treatment
SG174628A1 (en) * 2002-12-20 2011-10-28 Hoffmann La Roche High dose ibandronate formulation
CA2529558A1 (en) * 2003-07-01 2005-01-13 Astellas Pharma Inc. Agent inducing increase in bone mass
WO2005039485A2 (en) * 2003-08-13 2005-05-06 Chiron Corporation Gsk-3 inhibitors and uses thereof
JP2007534757A (en) * 2004-04-28 2007-11-29 メルク　エンド　カムパニー　インコーポレーテッド Fluorinated 4-azasteroids as androgen receptor modulators
WO2006004369A1 (en) * 2004-07-05 2006-01-12 Dong Wha Pharmaceutical. Ind. Co., Ltd. Pharmaceutical composition for the treatment of bone fracture
US7943646B2 (en) * 2006-01-31 2011-05-17 Dong Wha Pharmaceutical Co., Ltd. Benzamidine derivative, process for the preparation thereof and pharmaceutical composition comprising same
JP2009017222A (en) * 2007-07-04 2009-01-22 Panasonic Corp Color adjustment apparatus, color adjustment method, and integrated circuit of color adjustment apparatus
CA2694638A1 (en) * 2007-08-02 2009-02-05 Teijin Pharma Limited Preventive or therapeutic agent for diseases caused by abnormal bone metbolism
CA2732863A1 (en) * 2008-08-01 2010-02-04 Dong Wha Pharmaceutical Co., Ltd. A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivatives or their salts, and alendronic acid or its salt

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5451700A (en) * 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
US6150390A (en) * 1997-02-04 2000-11-21 Dong Wha Pharm. Ind. Co., Ltd. 3-amino-1,2-benzoisoxazole derivatives, process for preparation, and use thereof
WO2003007947A1 (en) * 2001-07-19 2003-01-30 Dong Wha Pharm. Ind. Co., Ltd. Use of 4-[(4-thiazolyl)phenoxl] alkoxy-benzamidine derivatives for treatment of osteoporosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DENNIS M. BLACK ET AL.: "The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 349, no. 13, 25 September 2003 (2003-09-25), pages 1207 - 1215, XP009045315 *
See also references of EP2307016A4 *

Also Published As

Publication number Publication date
KR20100014090A (en) 2010-02-10
WO2010013975A2 (en) 2010-02-04
EP2307016A4 (en) 2011-12-28
CA2732864A1 (en) 2010-02-04
CN102149381A (en) 2011-08-10
EP2307016A2 (en) 2011-04-13
JP2011529876A (en) 2011-12-15
KR20100014174A (en) 2010-02-10

Similar Documents

Publication Publication Date Title
WO2010013975A3 (en) A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivative or its salt, and bisphosphonate
WO2010111640A3 (en) Anti-influenza formulations and methods
WO2008070041A3 (en) Inhibitors of akt activity
WO2011028044A3 (en) Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
WO2011028043A3 (en) Pyrazole derivatives, preparation method thereof, and composition for prevention and treatment of osteoporosis containing same
WO2006135627A3 (en) Inhibitors of akt activity
WO2008127275A3 (en) Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof
WO2008014307A3 (en) Inhibitors of undecaprenyl pyrophosphate synthase
WO2010033977A3 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2012046030A3 (en) Phosphodiesterase inhibitors
MX2012003324A (en) Glycine compound.
WO2012158672A3 (en) Compounds for use in treatment of mucositis
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
WO2011149288A2 (en) Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases, and pharmaceutical composition containing same
WO2009114461A3 (en) Angiotensin (1-7) dosage forms and uses thereof
WO2011159137A3 (en) Novel thiourea or urea derivative, preparation method thereof, and pharmaceutical composition for preventing or treating aids, containing same as active ingredient
WO2008093709A1 (en) Composition for prevention or treatment of disease associated with amyloidosis through inhibition of aggregation amyloid protein and through promotion of degradation of amyloid protein
MX2010001116A (en) Novel benzamidine derivatives, process for the preparation thereof and pharmaceutical composition for preventing or treating osteoporosis comprising the same.
HK1205138A1 (en) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2009031819A3 (en) Composition for prevention or treatment of bone metabolism disorder comprising d-pinitol as an active ingredient
WO2009015446A3 (en) Triazole derivatives as viral replication inhibitors
WO2010042212A3 (en) Methods for treating or preventing pain using spicamycin derivatives
EP3964218A4 (en) Pharmaceutical composition for preventing or treating myositis, comprising isolated mitochondria as active ingredient
WO2012102560A3 (en) Novel 4-0-methylhonokiol derivative and composition containing same as active ingredient for treatment of inflammatory diseases
EP3895719A4 (en) Pharmaceutical composition comprising lactobacillus sakei wikim30 as active ingredient for prevention or treatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980133586.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09803180

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2732864

Country of ref document: CA

Ref document number: 2011521047

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009803180

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE